Mirabella Financial Services LLP Invests $4.50 Million in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mirabella Financial Services LLP purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,184 shares of the pharmaceutical company's stock, valued at approximately $4,501,000.

Several other hedge funds and other institutional investors also recently modified their holdings of VRTX. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Sugar Maple Asset Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $35,000. Golden State Wealth Management LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $37,000. Truvestments Capital LLC increased its position in Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after acquiring an additional 23 shares during the period. Finally, ORG Partners LLC raised its stake in Vertex Pharmaceuticals by 108.2% during the 4th quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock valued at $41,000 after acquiring an additional 53 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VRTX shares. BMO Capital Markets set a $545.00 price target on Vertex Pharmaceuticals in a report on Friday, January 31st. Truist Financial upped their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a research note on Tuesday, April 1st. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Finally, Morgan Stanley lifted their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 11th. Ten equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $514.91.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This trade represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Up 0.4 %

Shares of Vertex Pharmaceuticals stock traded up $1.95 during midday trading on Wednesday, hitting $492.42. The company's stock had a trading volume of 1,247,179 shares, compared to its average volume of 1,329,413. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $126.45 billion, a P/E ratio of -223.83, a PEG ratio of 2.11 and a beta of 0.50. The stock has a 50-day simple moving average of $487.81 and a 200-day simple moving average of $465.64.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.